Publication:
Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria

dc.contributor.coauthorCan, Pelin Kuteyla
dc.contributor.coauthorEtikan, Pırıl
dc.contributor.coauthorDeğirmentepe, Ece Nur
dc.contributor.departmentSchool of Medicine
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:36:27Z
dc.date.issued2024
dc.description.abstractBackground: Chronic spontaneous urticaria (CSU) is frequently associated with psychiatric comorbidities. Objective: We aimed to determine if depressive symptoms were present in CSU patients who received omalizumab and if depression scores got better with omalizumab treatment and whether the presence of depressive symptoms impaired treatment responses. Methods: CSU patients who received at least three injections of omalizumab were included in the study. Changes in Urticaria Activity Score (UAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q( 2 )oL), Beck Depression Inventory (Beck-D) and Urticaria Control Test (UCT) scores were compared before and after treatment. Results: From 49 patients, 20 (40.8%) had depressive symptoms at baseline. After treatment, UAS7, CU-Q (2 )oL, Beck-D scores decreased and UCT-scores increased significantly ( p < 0.001, for all). UCT scores were lower at baseline and at 3 (rd) month following treatment in patients with depressive symptoms compared to patients without (baseline median (interquartile range-IQR) 2.5 (1-5) vs 5 (2.5-6.5); p = 0.04 and 3 (rd) month 12 (9-13) vs 14 (12-16); p = 0.006, respectively). Omalizumab non-responders had higher baseline Beck -D -scores [18.5 (15.2-22) vs 12 (6-22.5); p = 0.031]. The number of omalizumab non-responders were significantly higher among patients with depressive symptoms compared to patients without. (40% vs 13.8%; p = 0.048). Only 6 patients scored as having depressive symptoms after treatment; of these 6 patients only one was an omalizumab responder. Conclusion: Omalizumab not only provides symptom control for urticaria but also improves psychological conditions of the patients. Coexistent psychiatric comorbidities should be taken into account in CSU patients since these conditions might impair treatment response.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.openaccessGreen Submitted, gold
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipFunding Sources This article has no funding source. This research did not receive any specific grant from funding agencies in the public, commercial, or not -for-profit sectors.
dc.description.volume42
dc.identifier.doi10.12932/ap-180920-0965
dc.identifier.eissn2228-8694
dc.identifier.issn0125-877X
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85196326860
dc.identifier.urihttps://doi.org/10.12932/ap-180920-0965
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22066
dc.identifier.wos1265656200004
dc.keywordsBiomarker
dc.keywordsDepression
dc.keywordsOmalizumab
dc.keywordsPsychiatric comorbidity
dc.keywordsUrticaria
dc.language.isoeng
dc.publisherAllergy Immunol Soc Thailand
dc.relation.ispartofAsian Pacific Journal Of Allergy And Immunology
dc.subjectAllergy
dc.subjectImmunology
dc.titleDepression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorKocatürk, Emek
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR04548.pdf
Size:
118.1 KB
Format:
Adobe Portable Document Format